Company Filing History:
1 out of 4,948 
1 out of 2 
1 out of 48 Years Active: 2020-2023
Title: Sebastian Kobold: Innovator in Cancer Therapy
Introduction
Sebastian Kobold is a prominent inventor based in Munich, Germany, known for his significant contributions to the field of cancer therapy. With a total of five patents to his name, he has made remarkable strides in the development of innovative medical treatments.
Latest Patents
Kobold's latest patents include groundbreaking inventions such as bispecific antibody molecules with antigen-transfected T-cells and their use in medicine. This invention provides a bispecific (monoclonal) antibody molecule with a first binding domain that targets an antigen on CD8+ T-cells, which does not naturally occur on these cells. The second binding domain targets a tumor-specific antigen found on the surface of tumor cells. These bispecific antibody molecules are particularly effective when used in combination with transduced CD8+ T-cells, which can carry antigens that do not naturally occur on CD8+ T-cells. This method offers a promising approach for treating specific diseases.
Another notable patent is related to CXCR6-transduced T cells for targeted tumor therapy. This invention involves transducing various types of T cells, including CD8+, CD4+, CD3+, γδ T cells, or natural killer (NK) T cells, for targeted tumor therapy. The patent also covers nucleic acid sequences and vectors capable of transducing these T cells, as well as methods and kits for their use. The transduced T cells expressing CXCR6 can be utilized in treating diseases characterized by CXCL16 overexpression, showcasing Kobold's innovative approach to cancer treatment.
Career Highlights
Throughout his career, Sebastian Kobold has worked with notable companies, including Hoffmann-La Roche Inc. His work has significantly impacted the field of immunotherapy, particularly in developing targeted treatments for cancer.
Collaborations
Kobold has collaborated with esteemed colleagues such as Stefan Endres and Christian Klein, contributing to the advancement of cancer therapies through their combined expertise.
Conclusion
Sebastian Kobold's innovative work in the field of cancer therapy, particularly through his patents on bispecific antibodies and transduced T cells, highlights his commitment to improving medical treatments. His contributions continue to pave the way for advancements in targeted cancer therapies.